PHILADELPHIA, March 16, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Alternext US:HEB) announced its financial results for the fiscal year ended December 31, 2008. The net loss for the year (including non-cash charges) was approximately $12,219,000 or $0.16 per share compared a net loss of $18,139,000 or $0.25 per share in 2007. This $5,920,000 reduction in loss was primarily due to: 1) $4,644,000 in lower research and development expenses with 2007 including significant costs related to the preparation of the Ampligen(r) New Drug Application ("NDA"); and 2) General and Administration expenses were lower by $2,496,000, as a result of a reduction program.
